目的 对多格列艾汀、二甲双胍和利格列汀进行临床综合评价,为医疗机构遴选药品提供依据。方法 依据《中国医疗机构药品评价与遴选快速指南(第二版)》,从药学特性、有效性、安全性、经济性和其他属性方面进行评分,根据评分结果,提出推荐意见。结果 多格列艾汀、二甲双胍和利格列汀最终得分分别为77.0、72.3、76.2分,均强推荐进入医疗机构采购目录或保留使用。3种药物均是口服降糖药物,在治疗2型糖尿病方面各有优势,二甲双胍是经典药物,在许多指南中受到一级推荐;多格列艾汀作为新药,在降糖效果及安全性方面有优势,在降糖的同时可改善患者β细胞功能;利格列汀作为保护胰岛β细胞功能的推荐药物,无需依据患者肝肾功能调整用药剂量。结论 多格列艾汀、二甲双胍和利格列汀在不同属性中各有优势,本次药品遴选可为医疗机构提供循证依据。

Objective To conduct a comprehensive clinical evaluation of dorzagliatin, metformin and linagliptin to provide a basis for the selection of drugs in medical institutions. Methods Based on the Rapid Guide for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition), the drugs were scored in terms of pharmacological properties, effectiveness, safety, economy and other attributes, and recommendations were made based on the scoring results. Results The final scores of dorzagliatin, metformin and linagliptin were 77.0, 72.3 and 76.2 respectively, and all of them were strongly recommended to be entered into the purchasing catalog of medical institutions or retained for use. The three drugs are oral hypoglycemic agents and each has its own advantages in the treatment of type 2 diabetes mellitus. Metformin is a classical drug and is recommended by the first class in many guidelines. As a new drug, dorzagliatin has advantages in glucose-lowering effect and safety, and it can improve patients' β -cell function while lowering glucose. Linagliptin is recommended as a drug to protect pancreatic β-cell function, and there is no need to adjust the dosage of the drug according to the patients' liver and kidney function. Conclusion Dorzagliatin, metformin and linagliptin have their own advantages in different attributes, and this drug selection can provide an evidence-based basis for medical institutions.

R977

国家自然科学基金资助项目(82003878);河北省卫健委医学研究指令性课题(20240157);河北省药学会医院药学科研项目(2020-Hbsyxhms0017)